Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of thymosin alpha 1 added to peginterferon alfa-2a and ribavirin in prior non-responders with chronic hepatitis C
2004-001277-25Phase 3Active
- Sponsor
- Leadiant Biosciences
- Start
- Apr 2005
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of thymosin alpha 1, peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by Leadiant Biosciences. Started Apr 2005; status: active.
02
Drugs
thymosin alpha 1peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2004-001277-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001277-25.